Veradigm

At a glance

Pricing

Custom enterprise (~$59/prescriber/mo entry modules).

HIPAA

Not disclosed

SOC 2

Not disclosed

EHRs

—

Founded

—

Bottom line

Population health + risk adjustment + real-world data (formerly Allscripts).

Free tier available.

Overview

Pricing

What it costs

Free tier only; no paid plans publicly disclosed.

Source: vendor pricing page. Verified May 23, 2026.

Vendor stability

Who builds it

It was previously known as Allscripts, an acquisition or rebrand that healthcare-AI buyers should track when reviewing prior independent coverage.

Peer-reviewed coverage

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate Veradigm in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry.

Bae JP, Kallenbach L, Nelson DR, et al.· BMC Endocr Disord· 2024

The proportion of heart failure patients with preserved ejection fraction has been rising over the past decades and has coincided with increases in the prevalence of obesity and metabolic syndrome. The relationship between these interconnected comorbidities and heart failure with preserved ejection fraction (HFpEF) is still poorly understood. This study characterized obesity and metabolic syndrome among real-world patients with HFpEF. We identified adults with heart failure in the Veradigm Cardiology Registry, previously the PINNACLE Registry, with a left ventricular ejection fraction measure…

Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.

Hunter Gibble T, Chinthammit C, Ward JM, et al.· Diabetes Obes Metab· 2025

To understand real-world tirzepatide use among individuals without type 2 diabetes (T2D) diagnoses in a US electronic health record (EHR) database. This retrospective, descriptive, cohort study used Veradigm's® Network EHR database linked with administrative claims. Adults (≥18 years) included had ≥1 tirzepatide prescription (index period: 13 May 2022-31 August 2023); continuous medical and pharmacy enrolment for ≥12 months pre-index; and no T2D diagnosis or baseline T2D medications except metformin (overall cohort). 'Anti-obesity medication (AOM)-eligi…

Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults.

Landi SN, Garofalo DC, Reimbaeva M, et al.· JAMA Netw Open· 2024

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory tract infections among adults and is estimated to cause approximately 159 000 hospitalizations among adults aged 65 years and older in the US each year. Estimates of hospitalization among adults with outpatient medically attended RSV (MA-RSV) infections are required to design interventional studies that aim to prevent hospitalization. To assess absolute risk of 28-day, all-cause hospitalization following outpatient MA-RSV infections in adults. In this cohort study, data from 3 different deidentified databases con…

Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes.

Tapper EB, Ryan T, Lewandowski D, et al.· BMC Gastroenterol· 2026

Metabolic dysfunction-associated steatohepatitis (MASH) is commonly comorbid with metabolic syndrome; however, MASH can occur in the absence of metabolic syndrome. This retrospective cohort study evaluated the patient characteristics, healthcare utilization, and healthcare costs among patients with MASH with and without metabolic syndrome, obesity, and type 2 diabetes/elevated fasting glucose. In a linked dataset of electronic health records (Veradigm Network EHR) and claims (Komodo Health), we identified adults with a MASH diagnosis code (7/1/2018-3/15/2023) and ≥12 months of continuo…

Assessing the impact of buprenorphine for opioid use disorder on infectious disease management.

Lo J, Thanataveerat A, Manfredo A, et al.· J Subst Use Addict Treat· 2026

Injection opioid misuse is associated with the transmission of infectious diseases (IDs) such as hepatitis B and C, and skin and soft tissue infections. Medications for opioid use disorder (MOUD) are effective treatments for opioid use disorder (OUD) and can reduce ID risk and improve outcomes. This study evaluated the association between treatment with buprenorphine extended-release (BUP-XR; SUBLOCADE®) or transmucosal buprenorphine (TM-BUP) and ID-specific incidence rates, all-cause healthcare resource utilization (HCRU), and ID-specific HCRU among patients treated for OUD continuously…

See all on PubMed